Radiotheranostics Global Market Report 2024

The radiotheranostics market size has grown rapidly in recent years. It will grow from $7.57 billion in 2023 to $8.74 billion in 2024 at a compound annual growth rate (CAGR) of 15.3%. The increase observed in the historical period can be attributed to advancements in nuclear medicine, a rise in cancer cases, the development of personalized medicine, progress in radiopharmaceuticals, and the establishment of regulatory approvals and standards.

The radiotheranostics market size is expected to see rapid growth in the next few years. It will grow to $14.61 billion in 2028 at a compound annual growth rate (CAGR) of 13.7%. The anticipated growth in the forecast period can be attributed to advancements in targeted cancer therapies, the expansion of oncology research, an increase in chronic diseases, and growth in theranostic applications. Prominent trends expected during the forecast period include the development of theranostic radiopharmaceuticals, extending applications beyond oncology, the customization of personalized radiopharmaceuticals, the integration of nanotechnology in radiotheranostics, and shifts in regulatory frameworks and standardization.

The projected increase in cancer prevalence is expected to drive the growth of the radiotheranostics market in the coming years. Cancer, characterized by uncontrolled cell growth and spread within the body, is a condition that necessitates targeted and personalized approaches for effective diagnosis and treatment. Radiotheranostics medications play a crucial role in cancer treatment by utilizing paired diagnostic and therapeutic radionuclide probes. This approach enables selective and targeted detection and treatment of specific cells, particularly cancer cells, tailored to the patient's unique condition. Cancer Research UK reported approximately 18 million new cancer cases in 2020, and global projections estimate 28 million new cases annually by 2040, reflecting a 54.9% increase from 2020. The rising prevalence of cancer serves as a significant driver for the expansion of the radiotheranostics market.

The increasing adoption of personalized medicine is poised to contribute to the growth of the radiotheranostics market. Personalized medicine, an innovative healthcare approach tailoring medical treatments to individual patient characteristics, is facilitated by radiotheranostics. This approach, utilizing specific radiopharmaceuticals, enables the identification of individualized molecular targets, allowing for precise diagnosis and tailored therapeutic interventions based on the patient's unique characteristics. In 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% classified as personalized medicines, according to the Personalized Medicine Coalition. The increasing adoption of personalized medicine is a key driver for the growth of the radiotheranostics market.

An emerging trend in the radiotheranostics market is the focus on product innovations. Major companies are directing their efforts towards creating innovative products to solidify their market positions. For instance, Advanced Cyclotron Systems Inc., a Canada-based company specializing in cyclotrons for medical isotope production, introduced TR-ALPHA in May 2023. This innovation is designed for the production of alpha-emitting radioisotopes used in cancer treatment. TR-ALPHA addresses market demands for a low-cost cyclotron capable of producing substantial amounts of Astatine-211, a promising alpha-emitting radioisotope. This product is smaller, more cost-effective, and easier to operate compared to previous cyclotron models, making it an ideal solution for efficiently producing therapeutic alpha-emitting radioisotopes.

Major companies in the radiotheranostics market are forming strategic partnerships to develop new products and strengthen their market positions. Collaborations and partnerships in this market facilitate the pooling of resources, expertise, and research efforts, accelerating the development, commercialization, and widespread adoption of advanced diagnostic and therapeutic solutions. In April 2022, Ion Beam Applications partnered with SCK CEN to advance the production of the radioisotope Actinium-225, a crucial element in cancer treatment. This collaboration aims to establish a state-of-the-art production facility in Mol, Belgium, combining expertise in particle accelerators and the provision of rare raw materials. Such collaborations are crucial for making radiotheranostic solutions commercially viable for treating various cancers with enhanced precision.

In June 2023, Ariceum Therapeutics GmbH, a Germany-based radiopharmaceutical company, acquired Theragnostics Ltd. for $41.5 million. This strategic acquisition is intended to broaden Ariceum's portfolio of therapeutic and diagnostic assets in late preclinical and early clinical development and expand its operations in the US. Theragnostics Ltd., a US-based radiopharmaceutical company, specializes in offering radio-theranostic solutions.

Major companies operating in the radiotheranostics market report are Lantheus Holdings Inc., Cardinal Health Inc., GE Healthcare Inc., Bayer AG, Novartis AG, Siemens Healthineers, Boston Scientific Corporation, Terumo Corporation, Orano Med, Curium SAS, IBA Molecular, The Eckert & Ziegler Group, Advanced Accelerator Applications (AAA), Telix Pharmaceuticals Limited., Abdera Therapeutics, Blue Earth Diagnostics, Sirtex Medical Limited, Y-mAbs Therapeutics Inc., ITM Radiopharma, NorthStar Medical Radioisotopes LLC, Trasis S.A., Molecular Targeting Technologies Inc., RadioMedix Inc., Clarity Pharmaceuticals, Actinium Pharmaceuticals Inc., Navidea Biopharmaceuticals Inc.

North America was the largest region in the radiotheranostics market in 2023. The regions covered in the radiotheranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radiotheranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary radiotheranostics radioisotopes include technetium-99, gallium-68, iodine-131, iodine-123, fludeoxyglucose-18F, yttrium-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. Technetium (Tc) is a silver-gray radioactive metal that occurs naturally at extremely low levels in the earth's crust but is predominantly man-made. It is used for skeletal and heart muscle scans and imaging of various organs such as the brain, thyroid, lungs, liver, spleen, kidneys, gall bladder, bone marrow, salivary and lacrimal glands, as well as in some specialized medical research. The different approaches include targeted therapeutic and targeted diagnostic applications in both oncology and non-oncology. The end users of this technology include hospitals and clinics, pharmaceutical and biotechnology companies, and others.

The radio theranostics market research report is one of a series of new reports that provides radio theranostics market statistics, including radio theranostics industry global market size, regional shares, competitors with a radio theranostics market share, detailed radio theranostics market segments, market trends, and opportunities, and any further data you may need to thrive in the radio theranostics industry. This radio theranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The radiotheranostics market consists of sales of iodine-125, radium-223 (223Ra), astatin-211 (211At), actinium-225 (225Ac), lead-212 (212Pb), bismuth-212 (212Bi), thorium-227, strontium-89 (89Sr), rhenium-188 (188Re), and samarium-153 (153Sm). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.